Appraisal of Olezarsen for Treatment of Hypertriglyceridemia

高甘油三酯血症 医学 内科学 甘油三酯 胆固醇
作者
Nasser Mikhail
标识
DOI:10.61797/ijetit.v5i1.334
摘要

Olezarsen is antisense antinucleotide under investigation that inhibits synthesis of apolipoprotein C3 (ApoC3) resulting in reduction of plasma triglycerides levels. In a phase 3 clinical trial of patients having familial chylomicronemia syndrome (FCS) with extreme hypertriglyceridemia at baseline (mean plasma triglycerides 2,630 mg/dl), olezarsen 80 mg administered subcutaneously every 4 weeks decreased triglycerides by 43.5 percentage points (95% CI, 69.1 to 17.9; P<0.001) after 6 months compared with placebo. By 53 weeks, 1 episode of acute pancreatitis occurred in olezarsen group versus 11 episodes in the placebo group, rate ratio (RR) 0.12 (95% CI, 0.02 TO 0.66). Two phase 2 trials evaluated olezarsen in patients with moderately elevated triglycerides (<500 mg/dl) and high cardiovascular (CV) risk recorded similar magnitude of reduction of triglycerides. Olezarsen reduced levels of atherogenic lipoproteins such as ApoC3 by 73%, non-high-density lipoprotein cholesterol (non-HDL-C) by 17-23% and increased high-density lipoprotein cholesterol (HDL-C) levels by 30-40%. Meanwhile, olezarsen increased mean values of low-density lipoprotein (LDL-C) from 22.8 to 37.6 mg/dl in patients with FCS but had no significant effects in patients with high CV risk having higher baseline LDL-C levels. Discontinuation rates due to adverse effects of olezarsen were 9-12% versus 0% with placebo. The most common adverse effects of olezarsen were elevation of liver enzymes, mostly below 3 times the upper limit of normal, and injection-site reactions. Platelet count < 140,000/µl occurred in 18% in patients receiving olezarsen versus 3% with placebo (risk ratio 6.8; 95% CI, 0.91 to 51.3; P=0.03). No patient had severe thrombocytopenia with platelet number < 75,000/µl. Overall, olezarsen is a promising new therapy for hypertriglyceridemia and for prevention of hypertriglyceridemia-induced pancreatitis. Long-term randomized trials are urgently needed to examine the effects of olezarsen on CV events and mortality and establish its long-term safety.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
delusionY完成签到 ,获得积分10
刚刚
kkkkpoa完成签到,获得积分10
1秒前
czxy完成签到,获得积分10
1秒前
冷艳的白凡完成签到 ,获得积分10
1秒前
Xp0836完成签到,获得积分10
1秒前
huchacha完成签到,获得积分10
1秒前
晏旭发布了新的文献求助10
1秒前
ww发布了新的文献求助10
1秒前
怕黑丹雪完成签到,获得积分10
1秒前
8旬老太快乐读研完成签到 ,获得积分10
2秒前
坚定秋荷完成签到,获得积分10
2秒前
2秒前
Minton完成签到,获得积分10
2秒前
Rainielove0215完成签到,获得积分0
2秒前
谷咕咕完成签到,获得积分10
2秒前
瓦达西瓦完成签到,获得积分10
3秒前
元复天完成签到 ,获得积分10
3秒前
Tang发布了新的文献求助10
3秒前
ha完成签到 ,获得积分10
4秒前
ppppp完成签到,获得积分10
4秒前
a水爱科研完成签到,获得积分10
4秒前
吴梦丽完成签到,获得积分10
4秒前
段甜完成签到 ,获得积分10
4秒前
Cherish完成签到,获得积分10
4秒前
媛媛完成签到,获得积分10
5秒前
zhangwenkang完成签到,获得积分10
5秒前
xhntt完成签到,获得积分10
5秒前
5秒前
开朗依柔完成签到,获得积分10
6秒前
CaiLing完成签到 ,获得积分10
6秒前
所所的应助被小王采纳,获得10
6秒前
碧落潮汐完成签到 ,获得积分10
6秒前
hehe完成签到,获得积分10
7秒前
天工王晨屹完成签到 ,获得积分10
7秒前
7秒前
丰富的甜瓜完成签到,获得积分10
7秒前
sengseng完成签到,获得积分10
7秒前
csy发布了新的文献求助10
7秒前
fanch1122完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042